Stem Cell Innovations (SCI) is a publicly-traded (SCLL.OB) cell biology company. The company is well positioned to become a leader in the development of next generation drug discovery solutions including human cellular disease models and cell-based therapies. SCI's proprietary stem cell platform named PluriCellsTM is capable of generating a broad range of differentiated human cell types. For example, cultures of human motor-neurons and human hepatocytes open up untapped therapeutic applications, and provide the basis of studying disease biology in a human model system. PluriCells have the potential to change the dynamics of drug discovery for diseases that include Parkinson's, Huntington's disease, multiple sclerosis, and hearing loss. SCI conducts internal R&D programs focused on neurological disorders and offers access to its research and technology through partnerships.
